These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 37355177)

  • 1. The correlation between gut and intra-tumor microbiota and PDAC: Etiology, diagnostics and therapeutics.
    Qian J; Zhang X; Wei B; Tang Z; Zhang B
    Biochim Biophys Acta Rev Cancer; 2023 Sep; 1878(5):188943. PubMed ID: 37355177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into the role of gut and intratumor microbiota in pancreatic ductal adenocarcinoma as new key players in preventive, diagnostic and therapeutic perspective.
    Panebianco C; Ciardiello D; Villani A; Maiorano BA; Latiano TP; Maiello E; Perri F; Pazienza V
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):997-1007. PubMed ID: 34838957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unraveling the gut microbiome's contribution to pancreatic ductal adenocarcinoma: mechanistic insights and therapeutic perspectives.
    Tabrizi E; Pourteymour Fard Tabrizi F; Mahmoud Khaled G; Sestito MP; Jamie S; Boone BA
    Front Immunol; 2024; 15():1434771. PubMed ID: 39044834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intestinal microbiota enhances pancreatic carcinogenesis in preclinical models.
    Thomas RM; Gharaibeh RZ; Gauthier J; Beveridge M; Pope JL; Guijarro MV; Yu Q; He Z; Ohland C; Newsome R; Trevino J; Hughes SJ; Reinhard M; Winglee K; Fodor AA; Zajac-Kaye M; Jobin C
    Carcinogenesis; 2018 Jul; 39(8):1068-1078. PubMed ID: 29846515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
    Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Immunological Glance on Pancreatic Ductal Adenocarcinoma.
    Melzer MK; Arnold F; Stifter K; Zengerling F; Azoitei N; Seufferlein T; Bolenz C; Kleger A
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The microbiota and microbiome in pancreatic cancer: more influential than expected.
    Wei MY; Shi S; Liang C; Meng QC; Hua J; Zhang YY; Liu J; Zhang B; Xu J; Yu XJ
    Mol Cancer; 2019 May; 18(1):97. PubMed ID: 31109338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapeutic strategies in pancreatic ductal adenocarcinoma (PDAC): current perspectives and future prospects.
    Nsingwane Z; Candy G; Devar J; Omoshoro-Jones J; Smith M; Nweke E
    Mol Biol Rep; 2020 Aug; 47(8):6269-6280. PubMed ID: 32661873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microbiome and pancreatic ductal adenocarcinoma.
    Tijeras-Raballand A; Hilmi M; Astorgues-Xerri L; Nicolle R; Bièche I; Neuzillet C
    Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101589. PubMed ID: 33607375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
    Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
    Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microbiome and pancreatic cancer: time to think about chemotherapy.
    de Castilhos J; Tillmanns K; Blessing J; Laraño A; Borisov V; Stein-Thoeringer CK
    Gut Microbes; 2024; 16(1):2374596. PubMed ID: 39024520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harnessing the Microbiome for Pancreatic Cancer Immunotherapy.
    Vitiello GA; Cohen DJ; Miller G
    Trends Cancer; 2019 Nov; 5(11):670-676. PubMed ID: 31735286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human microbiota colonization and pancreatic ductal carcinoma.
    Fang Y; Yang G; Yang J; Ren J; You L; Zhao Y
    Crit Rev Microbiol; 2023 Aug; 49(4):455-468. PubMed ID: 35924947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the microbiome in systemic therapy for pancreatic ductal adenocarcinoma (Review).
    Huang X; Li M; Hou S; Tian B
    Int J Oncol; 2021 Dec; 59(6):. PubMed ID: 34738624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles of microbiota in pancreatic cancer development and treatment.
    Cruz MS; Tintelnot J; Gagliani N
    Gut Microbes; 2024; 16(1):2320280. PubMed ID: 38411395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reshaping the Immune Microenvironment by Oncolytic Herpes Simplex Virus in Murine Pancreatic Ductal Adenocarcinoma.
    Zhang L; Wang W; Wang R; Zhang N; Shang H; Bi Y; Chen D; Zhang C; Li L; Yin J; Zhang H; Cao Y
    Mol Ther; 2021 Feb; 29(2):744-761. PubMed ID: 33130310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic ductal adenocarcinoma: Emerging therapeutic strategies.
    Osei-Bordom DC; Serifis N; Brown ZJ; Hewitt DB; Lawal G; Sachdeva G; Cloonan DJ; Pawlik TM
    Surg Oncol; 2022 Aug; 43():101803. PubMed ID: 35830772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes.
    Riquelme E; Zhang Y; Zhang L; Montiel M; Zoltan M; Dong W; Quesada P; Sahin I; Chandra V; San Lucas A; Scheet P; Xu H; Hanash SM; Feng L; Burks JK; Do KA; Peterson CB; Nejman D; Tzeng CD; Kim MP; Sears CL; Ajami N; Petrosino J; Wood LD; Maitra A; Straussman R; Katz M; White JR; Jenq R; Wargo J; McAllister F
    Cell; 2019 Aug; 178(4):795-806.e12. PubMed ID: 31398337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Tumor Microenvironment in Pancreatic Cancer Immunotherapy: Current Status and Future Perspectives.
    Poyia F; Neophytou CM; Christodoulou MI; Papageorgis P
    Int J Mol Sci; 2024 Sep; 25(17):. PubMed ID: 39273502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
    Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
    J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.